Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices
Top Cited Papers
- 1 January 2008
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 103 (1), 162-169
- https://doi.org/10.1111/j.1572-0241.2007.01556.x
Abstract
Fferentiate IBD patients with endoscopically assessed inflammation from IBD patients without inflammation and from irritable bowel syndrome (IBS); (b) whether they correlate with endoscopic severity of inflammation; and (c) whether a combination of fecal markers with the respective disease-specific activity indices may increase the diagnostic accuracy with reference to the endoscopic severity of inflammation. METHODS Fecal levels of Lf, Cal, and PMN-e and serum CRP were assessed in 139 patients undergoing diagnostic ileocolonoscopy (54 IBS patients, 42 ulcerative colitis [UC], 43 Crohn's disease [CD]). Disease activity was determined for CU with the colitis activity index (CAI) and for CD with the Crohn's disease activity index (CDAI). The performance of each marker with reference to endoscopic inflammatory activity was assessed by computing correlations, and sensitivity and specificity using published as well as adjusted cutoffs. A comprehensive activity index was computed by combining results from fecal markers, serum CRP, and a clinical activity index. RESULTS UC or CD patients with active inflammation demonstrated significantly higher levels of Lf, Cal, and PMN-e in feces as well as serum-CRP when compared to patients with inactive inflammation as well as patients with IBS (all P < 0.05). Using adjusted cutoffs enabled a marked improvement of all markers with an overall diagnostic accuracy in IBD of 80.0% for Lf, 80.0% for Cal, 74.1% for PMN-e, 64.0% for CRP, and 79.0% for the respective clinical disease scores. Cal showed the highest diagnostic accuracy in CD (81.4%), whereas Lf was superior to the other markers in UC (83.3%). The comprehensive activity index yielded a further improvement of sensitivity and specificity, with a diagnostic accuracy of 95.3% for UC patients. CONCLUSION The fecal markers Lf, Cal, and PMN-e are able to differentiate active IBD from inactive IBD as well as from IBS. None of these three stool markers is consistently superior in its ability to reflect endoscopic inflammation, but all three are superior to CRP in their diagnostic accuracy. A combination of the stool markers with the CRP and a disease-specific activity index in a categorical comprehensive activity index can increase the diagnostic accuracy with reference to the endoscopic inflammation in UC....Keywords
This publication has 44 references indexed in Scilit:
- Small bowel hydro‐MR imaging for optimized ileocecal distension in Crohn's disease: Should an additional rectal enema filling be performed?Journal of Magnetic Resonance Imaging, 2005
- Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritisExperimental Dermatology, 2005
- Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2004
- Fecal Lactoferrin Is A Sensitive and Specific Marker in Identifying Intestinal InflammationAmerican Journal of Gastroenterology, 2003
- Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteinsAmerican Journal of Gastroenterology, 2002
- Hydro-MRI in Crohn’s DiseaseInvestigative Radiology, 2000
- PMN-elastase in assessment of patients with inflammatory bowel diseaseDigestive Diseases and Sciences, 1993
- Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease.Gut, 1992
- Clinical Relevance of Activity Parameters in Crohn’s Disease Estimated by the Faecal Excretion of 111In-Labeled GranulocytesDigestion, 1991
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987